Table 1.

ROI activation data for the Novel vs. Fixation (NvF) contrast across four scanning sessions

Region	Extent of activation, % voxels activated, NvF				Magnitude of activation, % signal change, NvF
	Placebo 1	Placebo 2	Lorazepam	Scopolamine	Placebo 1	Placebo 2	Lorazepam	Scopolamine
Striate	66.0 (5.1)	64.3 (4.4)	60.3 (3.9)	62.2 (6.7)	0.29 (0.02)	0.29 (0.02)	0.31 (0.03)	0.30 (0.04)
Fusiform	33.3 (2.8)	33.9 (3.0)	20.9§ (2.9)	21.1§ (3.4)	0.20 (0.02)	0.22 (0.03)	0.13‡ (0.02)	0.12§ (0.03)
Hippocampal	15.3 (3.6)	10.7 (2.3)	6.1† (1.9)	6.0‡ (1.5)	0.08 (0.01)	0.06 (0.01)	0.03* (0.01)	0.03† (0.01)
Dorsolateral prefrontal	9.8 (2.7)	10.2 (2.9)	6.7 (1.8)	6.7 (2.3)	0.07 (0.02)	0.07 (0.02)	0.03* (0.02)	0.03* (0.02)
Inferior frontal	17.6 (5.3)	18.8 (6.3)	6.8‡ (2.9)	10.2* (3.9)	0.09 (0.02)	0.08 (0.02)	0.00§ (0.02)	0.03† (0.02)

Percent signal change is calculated for all voxels that activated in any of the four sessions. Numbers represent means with SEMs shown in parentheses. Significance values are based on a linear mixed-effects model, and are corrected for multiple comparisons:  

¹⁷⁸, P < 0.05;  

^†, P < 0.01;  

^‡, P < 0.001;  

^§, P < 0.0001.